FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

Data Compilation
#PharmaFlow

Pipeline Prospector 2025 highlights: FDA approves pill version of Novo’s Wegovy; BioMarin acquires Amicus for US$ 4.8 bn

Stock Recap
#PipelineProspector

Rivastigmine Tartrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

54 API Suppliers, 19 USDMF, 12 CEP/COS, 12 EU WC, 22 KDMF, 6 NDC API, 27 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

279 FDF Dossiers, 46 FDA Orange Book, 199 Europe, 29 Canada, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 10 DKSH, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 4 ACG Worldwide, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 39 Fillers, Diluents & Binders, 20 Thickeners and Stabilizers, 15 Direct Compression, 15 Controlled & Modified Release, 15 Lubricants & Glidants, 12 Granulation, 10 Co-Processed Excipients, 10 Film Formers & Plasticizers, 9 Empty Capsules, 9 Taste Masking, 8 Disintegrants & Superdisintegrants, 7 Chewable & Orodispersible Aids, 6 Emulsifying Agents, 5 Coloring Agents, 5 Topical, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Rheology Modifiers, 3 Solubilizers, 1 Surfactant & Foaming Agents, 1 Parenteral

DIGITAL CONTENT

7 News #PharmaBuzz

7 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 12 Regulatory FDF Prices

MARKET PLACE

3 APIs

3 APIs

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/01/2026	Interquim SA	Spain	Interquim, S.A. Sant Cugat Del Vallès ES	R1-CEP 2013-331 - Rev 00	Rivastigmine hydrogen tartrate	2020-01-23	Valid	Chemical		2630
29/01/2026	Dr. Reddy's Laboratories	India	DR. REDDY'S LABORATORIES LIMITED Hyderabad IN	R1-CEP 2013-305 - Rev 00	Rivastigmine hydrogen tartrate	2020-01-13	Valid	Chemical		2630

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Rivastigmine Tartrate

Rivastigmine Tartrate

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

54 API Suppliers

19 USDMF

12 CEP/COS

12 EU WC

22 KDMF

6 NDC API

27 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

8 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

279 FDF Dossiers

46 FDA Orange Book

199 Europe

29 Canada

5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

10 DKSH

3 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Kirsch Pharma

4 ACG Worldwide

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 BASF

10 Corel Pharma Chem

2 DFE Pharma

1 Finar

6 Gangwal Chemicals

4 Ideal Cures

2 Ingredion Pharma Solutions

10 Kerry

1 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

10 Microlex e.U

2 Nitika Pharmaceutical Specialities

1 Novo Excipients

1 Pharmatrans-Sanaq

3 Pluviaendo

2 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

17 Roquette

8 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

2 Silverline Chemicals

2 The Dow Chemical Company

1 Valens Pharmachem

2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives

39 Fillers, Diluents & Binders

20 Thickeners and Stabilizers

15 Direct Compression

15 Controlled & Modified Release

15 Lubricants & Glidants

12 Granulation

10 Co-Processed Excipients

10 Film Formers & Plasticizers

9 Empty Capsules

9 Taste Masking

8 Disintegrants & Superdisintegrants

7 Chewable & Orodispersible Aids

6 Emulsifying Agents

5 Coloring Agents

CAPSULE;ORAL - EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons